Drug Database · Clinicians

Memantine

Brands (23) Abixa, Memry, Alzhemed 10…Show all

US brand (reference label): memantine hydrochloride; not a Philippine-registered brand.

Anti-dementia (psychoanaleptic); Anti-demential; and others PH FDA category

Rx · Prescription drug26 PH productsPNF-listedVAT-exempt
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals
Label text on this page: US FDA-approved label via DailyMed/openFDA, set ID 72973b46-f307-4a9e-8fb1-ad2cbccfd736, version date November 1, 2018 (memantine hydrochloride · Actavis Pharma, Inc.). Reproduced verbatim. Philippine-approved indications and doses may differ: check the PH package insert.

Use: Labeled indications

  • Memantine hydrochloride tablets are indicated for the treatment of moderate to severe dementia of the Alzheimer’s type.
US FDA label
Full indications and usage US FDA label

1 INDICATIONS AND USAGE Memantine hydrochloride tablets are indicated for the treatment of moderate to severe dementia of the Alzheimer’s type. Memantine hydrochloride tablets are an N-methyl-D-aspartate (NMDA) receptor antagonist indicated for the treatment of moderate to severe dementia of the Alzheimer’s type. (1)

Contraindications

4 CONTRAINDICATIONS Memantine hydrochloride tablets are contraindicated in patients with known hypersensitivity to memantine hydrochloride or to any excipients used in the formulation. Memantine hydrochloride tablets are contraindicated in patients with known hypersensitivity to memantine hydrochloride or to any excipients used in the formulation. (4)

US FDA label

Dosing: Adult

Dosage and administration (US label) US FDA label

2 DOSAGE AND ADMINISTRATION The recommended starting dose of memantine hydrochloride tablets is 5 mg once daily. The dose should be increased in 5 mg increments to 10 mg/day (5 mg twice daily), 15 mg/day (5 mg and 10 mg as separate doses), and 20 mg/day (10 mg twice daily). The minimum recommended interval between dose increases is one week.

The dosage shown to be effective in controlled clinical trials is 20 mg/day. Memantine hydrochloride tablets can be taken with or without food. If a patient misses a single dose of memantine hydrochloride, that patient should not double up on the next dose. The next dose should be taken as scheduled. If a patient fails to take memantine hydrochloride tablets for several days, dosing may need to be resumed at lower doses and retitrated as described above.

Specific Populations Renal Impairment A target dose of 5 mg twice daily is recommended in patients with severe renal impairment (creatinine clearance of 5 – 29 mL/min based on the Cockcroft-Gault equation). Hepatic Impairment Memantine hydrochloride tablets should be administered with caution to patients with severe hepatic impairment [see Clinical Pharmacology (12.3)].

May be taken with or without food. (2) Initial dose is 5 mg once daily. Increase dose in 5 mg increments to a maintenance dose of 10 mg twice daily. A minimum of 1 week of treatment with the previous dose should be observed before increasing the dose. (2) Severe renal impairment: recommended dose is 5 mg twice daily. (2)

Dosing: Altered kidney function

From the US FDA label · Renal impairment (dosage and administration, pharmacokinetics)

Renal Impairment A target dose of 5 mg twice daily is recommended in patients with severe renal impairment (creatinine clearance of 5 – 29 mL/min based on the Cockcroft-Gault equation).

Renal Impairment Memantine pharmacokinetics were evaluated following single oral administration of 20 mg memantine hydrochloride in 8 subjects with mild renal impairment (creatinine clearance, CLcr, >50 – 80 mL/min), 8 subjects with moderate renal impairment (CLcr 30 – 49 mL/min), 7 subjects with severe renal impairment (CLcr 5 – 29 mL/min) and 8 healthy subjects (CLcr > 80 mL/min) matched as closely as possible by age, weight and gender to the subjects with renal impairment. Mean AUC 0- ∞ increased by 4%, 60%, and 115% in subjects with mild, moderate, and severe renal impairment, respectively, compared to healthy subjects.

The terminal elimination half-life increased by 18%, 41%, and 95% in subjects with mild, moderate, and severe renal impairment, respectively, compared to healthy subjects. No dosage adjustment is recommended for patients with mild and moderate renal impairment. Dosage should be reduced in patients with severe renal impairment [see Dosage and Administration (2)].

Kidney-specific guidance from renalcarematters.com: in preparation.

Dosing: Pediatric

Pediatric use (US label) US FDA label

8.4 Pediatric Use Safety and effectiveness in pediatric patients have not been established. Memantine failed to demonstrate efficacy in two 12-week controlled clinical studies of 578 pediatric patients aged 6-12 years with autism spectrum disorders (ASD), including autism, Asperger’s disorder and Pervasive Development Disorder - Not Otherwise Specified (PDD-NOS).

Memantine has not been studied in pediatric patients under 6 years of age or over 12 years of age. Memantine treatment was initiated at 3 mg/day and the dose was escalated to the target dose (weight-based) by week 6. Oral doses of memantine 3, 6, 9, or 15 mg extended-release capsules were administered once daily to patients with weights < 20 kg, 20-39 kg, 40-59 kg and ≥ 60 kg, respectively.

In a randomized, 12-week double-blind, placebo-controlled parallel study (Study A) in patients with autism, there was no statistically significant difference in the Social Responsiveness Scale (SRS) total raw score between patients randomized to memantine (n=54) and those randomized to placebo (n=53). In a 12-week responder-enriched randomized withdrawal study (Study B) in 471 patients with ASD, there was no statistically significant difference in the loss of therapeutic response rates between patients randomized to remain on full-dose memantine (n=153) and those randomized to switch to placebo (n=158).

The overall risk profile of memantine in pediatric patients was generally consistent with the known risk profile in adults [see Adverse Reactions (6.1)]. In Study A, the adverse reactions in the memantine group (n=56) that were reported in at least 5% of patients and at least twice the frequency of the placebo group (N=58) are listed in Table 2: Table 2: Study A Commonly Reported Adverse Reactions with a Frequency ≥ 5% and Twice That of Placebo A d vers e R eact i on M e m a n t in e N=56 P l a c e b o N=58 Cough 8.9% 3.4% Influenza 7.1% 3.4% Rhinorrhea 5.4% 0% Agitation 5.4% 1.7% D i sco n t inu at i o n s d u e to a d verse r e a ct i o n s a Aggression 3.6% 1.7% Irritability 1.8% 3.4% a Reported adverse reactions leading to discontinuation in more than one patient in either treatment group.

The adverse reactions that were reported in at least 5% of patients in the 12-48 week open-label study to identify responders to enroll in Study B are listed in Table 3: Table 3: 12-48 Week Open Label Lead-In study to Study B Commonly Reported Adverse Reactions with a Frequency ≥ 5% A d vers e R eact i on M e m a n t in e N=903 Headache 8.0% Nasopharyngitis 6.3% Pyrexia 5.8% Irritability 5.4% D i sco n t inu a t i o n s d u e to a dverse r e a ction s a Irritability 1.2% Aggression 1.0% a A t l ea st 1 % in c i d e n c e o f a d ve rse r eac tion s l ea din g t o p r e m a t u re d is c onti n u a t i on. In the randomized withdrawal study (Study B), the adverse reaction in patients randomized to placebo (n=160) and reported in at least 5% of patients and at twice the frequency of the full-dose memantine treatment group (n=157) was irritability (5.0% vs 2.5%).

Juvenile Animal Study In a study in which memantine (0, 15, 30 or 45 mg/kg/day) was orally administered to rats during the juvenile period of development (postnatal days [PND] 14 through 70), delays in sexual maturation were noted in males and females at all but the lowest dose tested, and body weight was reduced at the high dose. In rats orally administered memantine as a single dose (PND 14) or three daily doses (PND 14-16), neuronal lesions were observed in several areas of the brain at all but the lowest dose tested.

Adverse neurobehavioral effects (decreased auditory startle habituation) were observed at the high dose. The no-effect dose for developmental toxicity was the lowest dose tested (15 mg/kg/day). In a second juvenile animal study, memantine (0, 1, 3, 8, 15, 30, and 45 mg/kg/day) was orally administered to male and female rats beginning on PND 7 and continuing for various periods during postnatal development.

Because of early memantine-related mortality, the 30 and 45 mg/kg/day groups were terminated without further evaluation. Apoptosis or neuronal degeneration in the brain was observed on PNDs 8-17 at a dose of 15 mg/kg/day. The no-effect dose for apoptosis and neuronal degeneration was 8 mg/kg/day. In animals in which memantine (0, 1, 3, 8, or 15 mg/kg/day) was orally administered on PNDs 7-70, adverse neurobehavioral effects (increased locomotor motor activity, increased auditory startle response and decreased habituation, and deficit in learning and memory) were observed at all but the lowest dose tested.

Effects on auditory startle persisted after drug discontinuation. The no-effect dose for developmental toxicity was the lowest dose tested (1 mg/kg/day).

Dosing: Older adult

Geriatric use (US label) US FDA label

8.5 Geriatric Use The majority of people with Alzheimer’s disease are 65 years and older. In the clinical studies of memantine hydrochloride the mean age of patients was approximately 76; over 90% of patients were 65 years and older, 60% were 75 years and older, and 12% were at or above 85 years of age. The efficacy and safety data presented in the clinical trial sections were obtained from these patients. There were no clinically meaningful differences in most adverse events reported by patient groups ≥65 years old and <65 years old.

Dosage forms

Philippines

  • Film-coated tablet: 10 mg, 20 mg
  • Oral solution: 10 mg/mL

Registered products in the Philippines

26 products registered with the Food and Drug Administration (FDA) Philippines list Memantine as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Verify on PH FDA portal

All registered products26
Philippine FDA-registered products for Memantine
Package insert
AbixaMemantine hydrochloride
10 mg Film-Coated TabletAluminum/Polypropylene Blister Pack x 14's (Box of 28's); Aluminum/Polypropylene Blister Pack x 7's (Box of 7's) Physician's sample
RxVAT-exempt
Rottendorf Pharma GMBHGermany
Metro Drug, Inc.
DRP-9325
Oct 13, 2027
AbixaMemantine Hydrochloride
20 mg Film Coated TabletPP/Alu Blister Pack x 14's (Box of 14's and 28's)
RxVAT-exempt
Rottendorf Pharma GmbHGermany
Metro Drug, Inc.
DRP-9324
Jun 9, 2029
Alzhemed 10Memantine hydrochloride
10 mg Film-Coated TabletAlu/PVC/PVDC Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Unison Laboratories Co., Ltd.Thailand
Justright Healthcare Inc.
DR-XY47038
Oct 6, 2030
Alzhemed 20Memantine Hydrochloride
20 mg Film-Coated TabletAlu-PVC/PVDC Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Unison Laboratories Co., Ltd.Thailand
Justright Healthcare Inc.
DR-XY48928
Nov 22, 2028
Alzimed 10Memantine hydrochloride
10mg Film Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's)
RxVAT-exempt
CSPC Ouyi Pharmaceutical Co., Ltd.China
AMB HK Enterprises, Inc.Importer: AMB HK Enterprises Inc.
DRP-15366
Jun 27, 2029
Amint-10Memantine Hydrochloride
10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Torrent Pharmaceuticals Ltd.India
Torrent Pharma Philippines, Inc.
DRP-6443
Oct 8, 2027
CognitineMemantine Hydrochloride
10 mg Film-Coated TabletBlister Pack x 10's Box of 30's
RxVAT-exempt
Korea United Pharm. Inc.Korea
Littman Drug Corporation
DR-XY39738
Sep 17, 2031
DenigmaMemantine Hydrochloride
10 mg Film-Coated TabletAlu/PVC/PVDC Blister Pack X 14's (Box of 14's)
RxVAT-exempt
KUSUM HEALTHCARE PRIVATE LIMITEDIndia
KUSUM HEALTHCARE PRIVATE LIMITED BRANCH OFFICE
DR-XY44626
Jun 5, 2027
LeimentabMemantine Hydrochloride
10 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s Box of 30’s
RxVAT-exempt
Sydler Remedies Pvt. Ltd.India
Ambicare Pharmaceuticals Inc.Importer: Ambica International Corporation
DRP-6167-02
Jun 5, 2030
MemaMemantine Hydrochloride
10 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30’s)
RxVAT-exempt
Sydler Remedies Pvt. Ltd.India
Ambicare Pharmaceutical Inc.Importer: Ambica International Corporation
DRP-6167-07
Jun 5, 2030
Memadem-10Memantine Hydrochloride
10 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30’s)
RxVAT-exempt
Sydler Remedies Pvt. Ltd.India
Kipson Pharmaceutical TradingImporter: Ambica International Corporation
DRP-6167
Jun 5, 2030
MemalorMemantine Hydrochloride
10 mg Film-Coated TabletAlu/PVC/PVDC Blister pack x 8's (Box of 24's)
RxVAT-exempt
Hetero Labs Limited (Unit V)India
Camber Pharmaceuticals, Inc.
DRP-16844
Jul 16, 2030
MemandinMemantine Hydrochloride
10 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s Box of 30’s
RxVAT-exempt
Sydler Remedies Pvt. Ltd.India
Medchoice CNS Pharma CorporationImporter: Ambica International Corporation
DRP-6167-03
Jun 5, 2030
MemantaMemantine Hydrochloride
10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30’s)
RxVAT-exempt
Sydler Remedies Pvt. Ltd.India
The Cathay YSS Distributors Co., Inc.Importer: Ambica International Corporation
DRP-6167-06
Jun 5, 2030
Memarin 10Memantine Hydrochloride
10 mg Film-Coated TabletAlu/Clear PVC/PVDC blister pack x 14 's (Box of 42's); Alu/Clear PVC/PVDC blister pack x 10's (Box of 100's)
RxVAT-exempt
Genveon İlaç San. ve Tic. A.Ş.Turkey
Emcure Pharma Philippines Inc.Importer: Sandoz Philippines Corporation
DRP-7391-03
Oct 4, 2027
MemryMemantine Hydrochloride
10 mg / mL Oral Solution50 mL Type III Amber Glass Bottle with Pump (Box of 1's)
RxVAT-exempt
Chanelle MedicalIreland
UNILAB, Inc.
DR-XY48342
Sep 7, 2027
MemryMemantine Hydrochloride
10 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Bilim İlaç Sanayii Ve Ticaret A.Ş.Turkey
Unilab, Inc.
DR-XY42967
Nov 18, 2028
Memtin-DMemantine Hydrochloride
10 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30’s)
RxVAT-exempt
Sydler Remedies Pvt. Ltd.India
TGP Pharma Inc.Importer: Ambica International Corporation
DRP-6167-05
Jun 5, 2030
Mentra 10Memantine Hydrochloride
10 mg Film-Coated TabletAlu-PVDC Blister Pack x 10's (Box of 100's-Commercial pack)
RxVAT-exempt
Zydus Lifesciences LimitedIndia
Zydus Healthcare Philippines Inc.
DRP-7378
Apr 15, 2030
NoneMemantine Hydrochloride
10 mg Film-Coated TabletAlu/Clear PVC/PVDC Blister Pack x 10's Box of 100's
RxVAT-exempt
Genveon İlaç Sanayi ve Tic. A.Ş.Turkey
Ritemed Phils., Inc.Importer: Sandoz Philippines Corporation
DRP-7391-01
Oct 4, 2027
TimantineMemantine Hydrochloride
10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Titan Laboratories Pvt. Ltd.India
Aglobal Care, Inc.
DRP-13785
Apr 19, 2028
VexlinMemantine Hydrochloride
10 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30's)
RxVAT-exempt
Sydler Remedies Pvt. Ltd.India
VE Pharma Inc.Importer: Ambica International Corporation
DRP-6167-04
Jun 5, 2030
XapimantMemantine Hydrochloride
10 mg Film-Coated TabletAlu/Clear PVC/PVDC blister pack x 14 's (Box of 42's); Alu/Clear PVC/PVDC blister pack x 10's (Box of 100's)
RxVAT-exempt
Genveon İlaç Sanayi ve Tic. A.Ş.Turkey
Importer: Sandoz Philippines Corporation
DRP-7391
Oct 4, 2027
XolvmantineMemantine Hydrochloride
10 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30’s)
RxVAT-exempt
Sydler Remedies Pvt. Ltd.India
Xolvemed Pharma IncorporatedImporter: Ambica International Corporation
DRP-6167-01
Jun 5, 2030
ZemandeMemantine hydrochloride
10 mg Film-Coated TabletAlu / Clear PVC Blister Pack x 14’s (Box of 56’s)
RxVAT-exempt
The Schazoo Pharmaceutical Laboratories (Pvt) Ltd.Pakistan
Zuneca Incorporated
DRP-2787
Feb 11, 2030
ZimerzMemantine HCl
10 mg Film-Coated TabletAlu/PVC Blister Pack x 10's Box of 100's
RxVAT-exempt
ILDONG PHARMACEUTICAL CO., LTDRepublic of Korea
PATRIOT PHARMACEUTICALS CORP.Importer: PATRIOT PHARMACEUTICALS CORPORATION
DR-XY35289
Jul 21, 2030

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

United States (label)

Dosage forms and strengths (US label) US FDA label

3 DOSAGE FORMS AND STRENGTHS Memantine hydrochloride tablets 5 mg: capsule-shaped, film-coated tablets are tan, with the strength “5” debossed on one side and “FL” on the other side. Memantine hydrochloride tablets 10 mg: capsule-shaped, film-coated tablets are gray, with the strength “10” debossed on one side and “FL” on the other side. Tablets: 5 mg and 10 mg (3)

Warnings/Precautions

Warnings and precautions (US label) US FDA label

5 WARNINGS AND PRECAUTIONS Conditions that raise urine pH may decrease the urinary elimination of memantine, resulting in increased plasma levels of memantine. (5.1, 7.1) 5.1 Genitourinary Conditions Conditions that raise urine pH may decrease the urinary elimination of memantine resulting in increased plasma levels of memantine [see Drug Interactions (7.1)].

Drug interactions

Drug interactions (US label) US FDA label

7 DRUG INTERACTIONS 7. 1 Drugs that Make t he Urine Alkaline The clearance of memantine was reduced by about 80% under alkaline urine conditions at pH 8. Therefore, alterations of urine pH towards the alkaline condition may lead to an accumulation of the drug with a possible increase in adverse effects. Urine pH is altered by diet, drugs (e.g. carbonic anhydrase inhibitors, sodium bicarbonate) and clinical state of the patient (e.g. renal tubular acidosis or severe infections of the urinary tract).

Hence, memantine should be used with caution under these conditions. 7.2 Use with Other N-methyl-D-aspartate (NMDA) Antagonists The combined use of memantine hydrochloride with other NMDA antagonists (amantadine, ketamine, and dextromethorphan) has not been systematically evaluated and such use should be approached with caution.

Metabolism and transporters (CYP, P-gp, OATP; US label) US FDA label

The hepatic microsomal CYP450 enzyme system does not play a significant role in the metabolism of memantine.

Effect of Memantine Hydrochloride on the Metabolism of Other Drugs I n vitro studies conducted with marker substrates of CYP450 enzymes (CYP1A2, -2A6, -2C9, -2D6, -2E1, -3A4) showed minimal inhibition of these enzymes by memantine.

In addition, in vitro studies indicate that at concentrations exceeding those associated with efficacy, memantine does not induce the cytochrome P450 isozymes CYP1A2, -2C9, -2E1 and -3A4/5.

Memantine did not affect the pharmacokinetics of the CYP2B6 substrate bupropion or its metabolite hydroxy-bupropion.

Effect of Other Drugs on Memantine Hydrochloride Memantine is predominantly renally eliminated, and drugs that are substrates and/or inhibitors of the CYP450 system are not expected to alter the metabolism of memantine.

Adverse reactions

Adverse reactions (US label) US FDA label
  • Most common adverse reactions (≥ 5 % and greater than placebo) are dizziness, headache, confusion and constipation. (6.1)
  • To report SUSPECTED ADVERSE REACTIONS, contact Actavis at 1-800-272-5525 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
6.1 Clinical Trials Experience

6.1 Clinical Trials Experience Memantine hydrochloride was evaluated in eight double-blind placebo-controlled trials involving a total of 1862 dementia (Alzheimer’s disease, vascular dementia) patients (940 patients treated with memantine hydrochloride and 922 patients treated with placebo) for a treatment period up to 28 weeks. Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

Adverse Events Leading to Discontinuation In placebo-controlled trials in which dementia patients received doses of memantine hydrochloride up to 20 mg/day, the likelihood of discontinuation because of an adverse reaction was the same in the memantine hydrochloride group (10.1%) as in the placebo group (11.5%). No individual adverse reaction was associated with the discontinuation of treatment in 1% or more of memantine hydrochloride-treated patients and at a rate greater than placebo.

Most Common Adverse Reactions In double-blind placebo-controlled trials involving dementia patients, the most common adverse reactions (incidence ≥ 5% and higher than placebo) in patients treated with memantine hydrochloride were dizziness, headache, confusion and constipation. Table 1 lists all adverse reactions that occurred in at least 2% of patients treated with memantine hydrochloride and at an incidence greater than placebo.

Table 1: Adverse Reactions Reported in Controlled Clinical Trials in at Least 2% of Patients Receiving Memantine Hydrochloride and at a Higher Frequency than Placebo-treated Patients Adverse Reaction Placebo (N = 922) % Memantine H ydrochloride (N = 940) % Body as a Whole Fatigue 1 2 Pain 1 3 Cardiovascular System Hypertension 2 4 Central and Peripheral Nervous System Dizziness 5 7 Headache 3 6 Gastrointestinal System Constipation 3 5 Vomiting 2 3 Musculoskeletal System Back pain 2 3 Psychiatric Disorders Confusion 5 6 Somnolence 2 3 Hallucination 2 3 Respiratory System Coughing 3 4 Dyspnea 1 2 The overall profile of adverse reactions and the incidence rates for individual adverse reactions in the subpopulation of patients with moderate to severe Alzheimer’s disease were not different from the profile and incidence rates described above for the overall dementia population. Seizures Memantine hydrochloride has not been systematically evaluated in patients with a seizure disorder.

In clinical trials of memantine hydrochloride, seizures occurred in 0.2% of patients treated with memantine hydrochloride and 0.5% of patients treated with placebo.

6.2 Postmarketing Experience

6.2 Postmarketing Experience The following adverse reactions have been identified during post-approval use of memantine. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

These reactions include: Blood and Lymphatic System Disorders - agranulocytosis, leukopenia (including neutropenia), pancytopenia, thrombocytopenia, thrombotic thrombocytopenic purpura. Cardiac Disorders - cardiac failure congestive. Gastrointestinal Disorders - pancreatitis. Hepatobiliary Disorders - hepatitis. Psychiatric Disorders - suicidal ideation.

Renal and Urinary Disorders - acute renal failure (including increased creatinine and renal insufficiency). Skin Disorders - Stevens Johnson syndrome.

Adverse reaction frequency tables (US label) US FDA label
Table 1: Adverse Reactions Reported in Controlled Clinical Trials in at Least 2% of Patients Receiving Memantine Hydrochloride and at a Higher Frequency than Placebo-treated Patients
Adverse ReactionPlacebo (N = 922) %Memantine Hydrochloride (N = 940) %
Body as a Whole
Fatigue12
Pain13
Cardiovascular System
Hypertension24
Central and Peripheral Nervous System
Dizziness57
Headache36
Gastrointestinal System
Constipation35
Vomiting23
Musculoskeletal System
Back pain23
Psychiatric Disorders
Confusion56
Somnolence23
Hallucination23
Respiratory System
Coughing34
Dyspnea12

Pregnancy considerations

Pregnancy (US label) US FDA label

8.1 Pregnancy Risk Summary There are no adequate data on the developmental risk associated with the use of memantine hydrochloride in pregnant women. Adverse developmental effects (decreased body weight, and skeletal ossification) were observed in the offspring of rats administered memantine during pregnancy at doses associated with minimal maternal toxicity.

These doses are higher than those used in humans at the maximum recommended daily dose of memantine hydrochloride [see Data]. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. The background risk of major birth defects and miscarriage for the indicated population is unknown.

Data Animal Data Oral administration of memantine (0, 2, 6, or 18 mg/kg/day) to rats during the period of organogenesis resulted in decreased skeletal ossification in fetuses at the highest dose tested. The higher no-effect dose for adverse developmental effects (6 mg/kg) is 3 times the maximum recommended human daily dose (MRHD) of memantine hydrochloride (20 mg) on a body surface area (mg/m 2) basis.

Oral administration of memantine to rabbits (0, 3, 10, or 30 mg/kg/day) during the period of organogenesis resulted in no adverse developmental effects. The highest dose tested is approximately 30 times the MRHD of memantine hydrochloride on a mg/m 2 basis. In rats, memantine (0, 2, 6, or 18 mg/kg/day) was administered orally prior to and throughout mating and, in females, through the period of organogenesis or continuing throughout lactation to weaning.

Decreased skeletal ossification in fetuses and decreased body weight in pups were observed at the highest dose tested. The higher no-effect dose for adverse developmental effects (6 mg/kg/day) is 3 times the MRHD of memantine hydrochloride on a mg/m 2 basis. Oral administration of memantine (0, 2, 6, or 18 mg/kg/day) to rats from late gestation throughout lactation to weaning, resulted in decreased pup weights at the highest dose tested.

The higher no-effect dose (6 mg/kg/day) is approximately 3 times the MRHD of memantine hydrochloride on a mg/m 2 basis.

Mechanism of action

12.1 Mechanism of Action Persistent activation of central nervous system N-methyl-D-aspartate (NMDA) receptors by the excitatory amino acid glutamate has been hypothesized to contribute to the symptomatology of Alzheimer’s disease. Memantine is postulated to exert its therapeutic effect through its action as a low to moderate affinity uncompetitive (open-channel) NMDA receptor antagonist which binds preferentially to the NMDA receptor-operated cation channels. There is no evidence that memantine prevents or slows neurodegeneration in patients with Alzheimer’s disease.

US FDA label

Pharmacodynamics

Pharmacodynamics (US label) US FDA label

12.2 Pharmacodynamics Memantine showed low to negligible affinity for GABA, benzodiazepine, dopamine, adrenergic, histamine and glycine receptors and for voltage-dependent Ca 2+, Na + or K + channels. Memantine also showed antagonistic effects at the 5HT 3 receptor with a potency similar to that for the NMDA receptor and blocked nicotinic acetylcholine receptors with one-sixth to one-tenth the potency. In vitro studies have shown that memantine does not affect the reversible inhibition of acetylcholinesterase by donepezil, galantamine, or tacrine.

Pharmacokinetics

Half-life and elimination (verbatim, US label)

Elimination Memantine is excreted predominantly (about 48%) unchanged in urine and has a terminal elimination half- life of about 60-80 hours.

A total of 74% of the administered dose is excreted as the sum of the parent drug and the N-glucuronide conjugate.

Renal clearance involves active tubular secretion moderated by pH dependent tubular reabsorption.

The terminal elimination half-life increased by 18%, 41%, and 95% in subjects with mild, moderate, and severe renal impairment, respectively, compared to healthy subjects.

However, terminal elimination half-life increased by about 16% in subjects with moderate hepatic impairment as compared with healthy subjects.

Pharmacokinetics (US label) US FDA label

12.3 Pharmacokinetics Absorption Following oral administration memantine is highly absorbed with peak concentrations reached in about 3-7 hours. Memantine has linear pharmacokinetics over the therapeutic dose range. Food has no effect on the absorption of memantine. Distribution The mean volume of distribution of memantine is 9-11 L/kg and the plasma protein binding is low (45%).

Metabolism Memantine undergoes partial hepatic metabolism. The hepatic microsomal CYP450 enzyme system does not play a significant role in the metabolism of memantine. Elimination Memantine is excreted predominantly (about 48%) unchanged in urine and has a terminal elimination half- life of about 60-80 hours. The remainder is converted primarily to three polar metabolites which possess minimal NMDA receptor antagonistic activity: the N-glucuronide conjugate, 6-hydroxy memantine, and 1-nitroso-deaminated memantine.

A total of 74% of the administered dose is excreted as the sum of the parent drug and the N-glucuronide conjugate. Renal clearance involves active tubular secretion moderated by pH dependent tubular reabsorption. Pharmacokinetics in Speci fic Populations Gender Following multiple dose administration of memantine hydrochloride 20 mg daily, females had about 45% higher exposure than males, but there was no difference in exposure when body weight was taken into account.

Elderly The pharmacokinetics of memantine hydrochloride in young and elderly subjects are similar. Renal Impairment Memantine pharmacokinetics were evaluated following single oral administration of 20 mg memantine hydrochloride in 8 subjects with mild renal impairment (creatinine clearance, CLcr, >50 – 80 mL/min), 8 subjects with moderate renal impairment (CLcr 30 – 49 mL/min), 7 subjects with severe renal impairment (CLcr 5 – 29 mL/min) and 8 healthy subjects (CLcr > 80 mL/min) matched as closely as possible by age, weight and gender to the subjects with renal impairment.

Mean AUC 0- ∞ increased by 4%, 60%, and 115% in subjects with mild, moderate, and severe renal impairment, respectively, compared to healthy subjects. The terminal elimination half-life increased by 18%, 41%, and 95% in subjects with mild, moderate, and severe renal impairment, respectively, compared to healthy subjects.

No dosage adjustment is recommended for patients with mild and moderate renal impairment. Dosage should be reduced in patients with severe renal impairment [see Dosage and Administration (2)]. Hepatic Impairment Memantine pharmacokinetics were evaluated following the administration of single oral doses of 20 mg in 8 subjects with moderate hepatic impairment (Child-Pugh Class B, score 7-9) and 8 subjects who were age-, gender-, and weight-matched to the hepatically-impaired subjects.

There was no change in memantine exposure (based on C max and AUC) in subjects with moderate hepatic impairment as compared with healthy subjects. However, terminal elimination half-life increased by about 16% in subjects with moderate hepatic impairment as compared with healthy subjects. No dose adjustment is recommended for patients with mild and moderate hepatic impairment.

Memantine should be administered with caution to patients with severe hepatic impairment as the pharmacokinetics of memantine have not been evaluated in that population. Drug-Drug Interactions Use with Cholinesterase Inhibitors Coadministration of memantine with the AChE inhibitor donepezil hydrochloride did not affect the pharmacokinetics of either compound.

Furthermore, memantine did not affect AChE inhibition by donepezil. In a 24-week controlled clinical study in patients with moderate to severe Alzheimer’s disease, the adverse event profile observed with a combination of memantine hydrochloride and donepezil was similar to that of donepezil alone. Effect of Memantine Hydrochloride on the Metabolism of Other Drugs I n vitro studies conducted with marker substrates of CYP450 enzymes (CYP1A2, -2A6, -2C9, -2D6, -2E1, -3A4) showed minimal inhibition of these enzymes by memantine.

In addition, in vitro studies indicate that at concentrations exceeding those associated with efficacy, memantine does not induce the cytochrome P450 isozymes CYP1A2, -2C9, -2E1 and -3A4/5. No pharmacokinetic interactions with drugs metabolized by these enzymes are expected. Pharmacokinetic studies evaluated the potential of memantine for interaction with warfarin, and bupropion.

Memantine did not affect the pharmacokinetics of the CYP2B6 substrate bupropion or its metabolite hydroxy-bupropion. Furthermore, memantine did not affect the pharmacokinetics or pharmacodynamics of warfarin as assessed by the prothrombin INR. Effect of Other Drugs on Memantine Hydrochloride Memantine is predominantly renally eliminated, and drugs that are substrates and/or inhibitors of the CYP450 system are not expected to alter the metabolism of memantine.

Drugs Eliminated via Renal Mechanisms Because memantine is eliminated in part by tubular secretion, coadministration of drugs that use the same renal cationic system, including hydrochlorothiazide (HCTZ), triamterene (TA), metformin, cimetidine, ranitidine, quinidine, and nicotine, could potentially result in altered plasma levels of both agents. However, coadministration of memantine hydrochloride and HCTZ/TA did not affect the bioavailability of either memantine or TA, and the bioavailability of HCTZ decreased by 20%.

In addition, coadministration of memantine with the antihyperglycemic drug Glucovance ® (glyburide and metformin hydrochloride) did not affect the pharmacokinetics of memantine, metformin and glyburide. Furthermore, memantine did not modify the serum glucose lowering effect of Glucovance ®, indicating the absence of a pharmacodynamic interaction.

Drugs Highly Bound to Plasma Proteins Because the plasma protein binding of memantine is low (45%), an interaction with drugs that are highly bound to plasma proteins, such as warfarin and digoxin, is unlikely.

Formulary and pricing (Philippines)

Government price references

PreparationPrice (PHP)UnitType
Memantine 10 mg Film coated tablet₱15.00–₱18.00Reference ₱18.00per tabletDPRI procurement range

Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)

These are government procurement and reimbursement references, not retail prices. Sources:

Formulary and coverage

Philippine National FormularyListed as Memantine
PNF listingOral: 5 mg and 10 mg film coated tablet
PhilHealth GAMOTNo

Sources:

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. U.S. Food and Drug Administration. memantine hydrochloride · Actavis Pharma, Inc. [US FDA-approved label, version 10, November 1, 2018]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=72973b46-f307-4a9e-8fb1-ad2cbccfd736
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
  3. PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
  4. DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf

This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .